BackKeros Therapeutics Overview
Keros Therapeutics Inc

Keros Therapeutics Target Price

Analysts' average 12-month price target for Keros Therapeutics is $20.

Get informed when a big investor buys or sells

+ Follow

Share Price

$11.32

Average Target Price

$20.3379.6% upside

3 analysts in the last 4 months

High: $23 | Low: $18

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-04Wells FargoBenjamin Burnett$1859% upsideOpen
2026-08-04H.C. WainwrightAndrew Fein$2076.7% upsideOpen
2026-08-04Leerink Partners$23103.2% upsideOpen
2024-11-05JefferiesKelly Shi$107845.2% upsideOpen
2024-11-05Truist FinancialSrikripa Devarakonda$100783.4% upsideOpen
2024-09-23GuggenheimVamil Divan$96748.1% upsideOpen
2024-06-18Piper SandlerJoseph Catanzaro$105827.6% upsideOpen
2022-12-13BTIG$105827.6% upsideOpen
2022-07-27BTIGJulian Harrison$80606.7% upsideOpen
2022-05-18Piper SandlerJoseph Catanzaro$120960.1% upsideOpen

Keros Therapeutics (KROS) FAQ

As of the most recent data, KROS shows a target price of $20. Scroll down for historical charts and peer comparison views.

If Keros Therapeutics moved to the average analyst target of $20, shares would be roughly 79.6% higher than $11.32. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Keros Therapeutics's earnings trajectory.

Besides this target price page, Stockcircle has Keros Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $20) with ownership activity and broader fundamentals.

Keros Therapeutics's target price is $20; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.